HOME >> MEDICINE >> NEWS
Study examines three-day antibiotic regimens for treating bladder infection in women

CHICAGO A three-day regimen of the antibiotic amoxicillin-clavulanate is not as effective as ciprofloxacin at treating an uncomplicated bladder infection in women, according to a study in the February 23 issue of JAMA.

Acute uncomplicated urinary tract infections (UTIs) are among the most commonly encountered bacterial infections in women, according to background information in the article. Management of these infections has been made more complicated in recent years by increasing antimicrobial resistance, which has led to increased use of alternative antibiotics. There have been no published studies on the efficacy of one such antibiotic, amoxicillin-clavulanate, in the treatment of acute cystitis (inflammation of the urinary bladder) in the current era of high-level amoxicillin resistance.

Thomas M. Hooton, M.D., of the University of Washington and Harborview Medical Center, Seattle, and colleagues conducted a randomized trial that compared 3-day regimens of amoxicillin-clavulanate and ciprofloxacin for treatment of women with acute uncomplicated cystitis and used follow-up to evaluate the women for recurrent infection. Ciprofloxacin is in the fluoroquinolone class of antibiotics, a potent and frequently prescribed group that has shown increasing resistance. The trial included 370 women, aged 18 to 45 years. Subjects were randomly assigned to receive amoxicillin-clavulanate (500 mg/125 mg twice daily) or ciprofloxacin (250 mg twice daily) for 3 days and were followed for 4 months.

The researchers found that clinical cure resolution of the symptoms associated with UTI was observed in 93 (58 percent) of 160 women treated with amoxicillin-clavulanate compared with 124 (77 percent) of 162 women treated with ciprofloxacin. Amoxicillin-clavulanate was not as effective as ciprofloxacin even among women infected with bacterial strains susceptible to amoxicillin-clavulanate (65 [60 percent] of 109 women in the amoxicillin-clavulanate group vs. 114
'"/>

Contact: Susan Gregg-Hanson
206-731-4097
JAMA and Archives Journals
22-Feb-2005


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:4/1/2015)... 2015 San Francisco based sustainable medical ... medical charity, Operation Smile, have launched a ... Campaign Details: RxOrganics is generously donating 5% of ... Operation Smile throughout 2015. RxOrganics has committed to an ... that every order placed online through the Rxmedical shop ...
(Date:4/1/2015)... April 01, 2015 Results are in ... , which featured 11 new homes from across the ... that best utilized innovative building techniques and new technology ... Steven Winter Associates, Inc. (SWA) provided sustainability consulting services ... year’s challenge, including the first- and third-place winners. , ...
(Date:4/1/2015)... 01, 2015 Poisonous plants (poison ivy, ... change in recent years, increasing significantly in number and ... if exposed to poison plants (according to the American ... prepare for summer adventures in nature, they should be ... reaction is greater than ever. This year, Ivarest adds ...
(Date:3/31/2015)... Bon Secours New York Health System ... Nursing Care Center family last week. The Sisters formerly ... Yonkers which is scheduled to close later this year. ... the Sisters of Charity of New York, the decision ... place their Sisters at Schervier Nursing Care Center followed ...
(Date:3/31/2015)... As the demand for optimized mobile content ... a mobile-friendly website online sometime during the month of ... continued commitment to bring the best and most accurate ... the same great fitness information at http://www.chunkfitness.com ... to read while browsing on a mobile device. , ...
Breaking Medicine News(10 mins):Health News:RxOrganics Forges Unique Partnership to Bring More Smiles to Underserved Global Heath Communities 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 3Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 4Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2
(Date:3/31/2015)... 2015 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... exclusive collaboration and licensing agreement for the development and ... Japan and other select Asian markets with ... to initially develop NBI-98854 in Japan ... tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 ...
(Date:3/31/2015)... UHC has released the findings of a ... based on cost and quality outcomes to uncover several ... study examined utilization of PPIs—which can account for 30% ... 10 academic medical centers, focusing on procedures utilizing orthopedic ... The study, begun in 2013, integrated the ...
(Date:3/31/2015)... N.Y., March 31, 2015 Uroplasty, Inc. (NASDAQ: ... the completion of their merger. The merger was ... the all-stock combination creates a new medical device ... 1, 2015, Cogentix Medical, Inc. will trade on ... will have its U.S. headquarters in ...
Breaking Medicine Technology:Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
Cached News: